GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Antibiotice SA (BSE:ATB) » Definitions » Capex-to-Operating-Cash-Flow
中文

Antibiotice (BSE:ATB) Capex-to-Operating-Cash-Flow : 0.73 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Antibiotice Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Antibiotice's Capital Expenditure for the three months ended in Dec. 2023 was lei-44.72 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was lei60.93 Mil.

Hence, Antibiotice's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2023 was 0.73.


Antibiotice Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Antibiotice's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibiotice Capex-to-Operating-Cash-Flow Chart

Antibiotice Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.35 0.51 0.65 0.39 0.80

Antibiotice Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.65 0.68 0.73

Competitive Comparison of Antibiotice's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Antibiotice's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibiotice's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Antibiotice's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Antibiotice's Capex-to-Operating-Cash-Flow falls into.



Antibiotice Capex-to-Operating-Cash-Flow Calculation

Antibiotice's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-98.037) / 122.459
=0.80

Antibiotice's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-44.718) / 60.931
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antibiotice  (BSE:ATB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Antibiotice Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Antibiotice's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibiotice (BSE:ATB) Business Description

Traded in Other Exchanges
N/A
Address
1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice Ord is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).

Antibiotice (BSE:ATB) Headlines

No Headlines